Select acquires remainder of subsidiaries

By Melissa Trudinger
Tuesday, 30 November, 2004

Select Vaccines (ASX: SLT) will acquire the remaining 35 per cent of its two subsidiaries Picoral and Hepgenics from the Burnet Institute.

The institute will be issued 4 million new shares plus 2 million options in Select Vaccines in return for its equity.

Ongoing R&D programs being conducted by the Burnet Institute for the two companies will continue to be funded through December 2005.

The new 4500 sqm RNA Research and Manufacturing Facility within the Macquarie University...

To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...

Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...

Content from other channels on our network

Food waste creates premium shiraz

University uses AI to accelerate solar panel recycling

Visy reaches 70% recycled content target again for NZ glass

What the Japanese bullet train can teach us about cutting emissions

NSW Govt to fast-track renewable energy project deliveries

Coca-Cola Europacific Partners leads Pacific PET circularity program

Adversaries leveraging public AI tools to target OT systems

ABB Robotics launches automated surface finishing cell

Siemens expands digital water solutions

Government announces expanded minerals cooperation with Japan

As AI reshapes health care, human skills are more important than ever

Optometry Australia to unify into single national entity

NSW announces review into 'stranded' aged care patients

PASA Health & Aged Care Procurement Conference returns in June

Why Some People Thrive in High-Energy Environments, and Others Need to Stay Calm